Document is current

Article History

Received: 8 August 2019

Accepted: 27 March 2020

First Online: 7 April 2020

Ethics approval and consent to participate

: Protocols for all trials were approved by the appropriate ethics committees/institutional review boards, and each patient provided written informed consent before participation in their study. The studies were conducted in compliance with institutional review board regulations, the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki.

: Not applicable

: CG received research grants from AB2 Bio, Pfizer and Roche and consulting fees or other remuneration from AB2 Bio, AbbVie, Bristol Myers Squibb, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi and UCB. GRB has received research grants from AbbVie, Pfizer, UCB and Roche and consulting fees or other remuneration from AbbVie, Lilly, MSD, Pfizer, Sanofi, Roche and UCB. VS received consulting fees from AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Celltrion, CORRONA, Crescendo, Genentech/Roche, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., Sandoz, Sanofi and UCB. JM is an employee of Sanofi and may hold stock and/or stock options in the company. MZ and HvH are employees of Sanofi Genzyme and may hold stock and/or stock options in the company. JS is a former employee of Sanofi Genzyme and may hold stock and/or stock options in the company and is currently employed by Bristol Myers Squibb. TK, SHB, NMHG and AB are employees of Regeneron Pharmaceuticals, Inc. and may hold stock and/or stock options in the company.